Interaksi Beksaroten

Acitretin is contraindicated in cases of hypersensitivity (e.g., angioedema, urticaria) to the preparation (acitretin or excipients) or to other retinoids . (label Asitretin, Kontraindikasi)

Because of a potential drug-drug interaction, avoid gemfibrozil use with TARGRETIN [ see Drug Interactions (7) ]. (label Beksaroten, Peringatan dan perhatian)

Avoid concomitant use of isotretinoin and EMROSI because isotretinoin, a systemic retinoid, is also known to cause idiopathic intracranial hypertension. (label Minosiklin, Peringatan dan perhatian)

Concomitant use of isotretinoin and tetracycline should be avoided because isotretinoin, a systemic retinoid, is also known to cause pseudotumor cerebri. (label Tetrasiklin, Peringatan)

Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. (label Tretinoin, Kontraindikasi)

Patients with CTCL who have risk factors for pancreatitis (e.g., prior pancreatitis, uncontrolled hyperlipidemia, excessive alcohol consumption, uncontrolled diabetes mellitus, biliary tract disease, and medications known to increase triglyceride levels or to be associated with pancreatic toxicity) may be at greater risk for pancreatitis associated with TARGRETIN… (label Beksaroten, Peringatan dan perhatian)

Patients with elevated vitamin A levels may be at increased risk. (label Eleksakaftor, tezakaftor, dan ivakaftor, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Patients with elevated vitamin A levels may be at increased risk. (label Ivakaftor, Peringatan dan perhatian)

Drugs That Increase the Risk of Hypercalcemia Increase frequency of monitoring of calcium concentrations in patients taking concomitant Calcium Chloride Injection and other drugs that increase the risk of hypercalcemia (e.g., calcipotriene, estrogen, lithium, parathyroid hormone, teriparatide, thiazide diuretics, Vitamin A, and Vitamin D). (label Kalsium klorida, Interaksi obat)

Monitor and replace thyroid hormone if needed. (label Beksaroten, Peringatan dan perhatian)

Monitor and replace thyroid hormone if needed. (label Beksaroten, Peringatan dan perhatian)

Monitor and replace thyroid hormone if needed. (label Beksaroten, Peringatan dan perhatian)

Monitor patients receiving XATMEP with other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) for possible signs of hepatotoxicity. (label Metotreksat, Interaksi obat)

The effect of ORLISTAT on the absorption of supplemental vitamin D, vitamin A, and nutritionally-derived vitamin K is not known at this time [see Clinical Pharmacology (12.3) , and Warnings and Precautions (5.1) ] . (label Orlistat, Interaksi obat)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Monitor and replace thyroid hormone if needed. (label Beksaroten, Peringatan dan perhatian)

Monitor and replace thyroid hormone if needed. (label Beksaroten, Peringatan dan perhatian)

Monitor and replace thyroid hormone if needed. (label Beksaroten, Peringatan dan perhatian)

Hypoglycemia Risk in Patients with Diabetes Mellitus In patients using insulin, agents enhancing insulin secretion (e.g., sulfonylureas), or insulin sensitizers (e.g., thiazolidinedione class), based on the mechanism of action, TARGRETIN could enhance the action of these agents, resulting in hypoglycemia. (label Beksaroten, Peringatan dan perhatian)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (label Beksaroten, Peringatan dan perhatian)

Atorvastatin was used in 48% (73/152) of patients with CTCL. (label Beksaroten, Peringatan dan perhatian)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Vitamin A Based on a case report in one patient receiving combination therapy with all-trans-retinoid acid (an acid form of vitamin A) and fluconazole, central nervous system (CNS) related undesirable effects have developed in the form of pseudotumor cerebri, which disappeared after discontinuation of fluconazole treatment. (label Flukonazol, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drugs that may cause hypercalcemia: Vitamin D, vitamin A, thiazide diuretics, estrogen, calcipotriene and teriparatide administration may cause hypercalcemia. (label Kalsium glukonat, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)

Drug products which may be affected include oral or other systemic hormonal contraceptives. (label Beksaroten, Interaksi obat)